Table 3 Characteristics of patients with RA.
Patient | Sex | Age (y) | Disease duration (y) | WBC (/mm3) | CRP (mg/dl) | Anti-CCP Ab (U/ml) | MMP3 (ng/ml) | RF (mg/dl) | Treatment |
|---|---|---|---|---|---|---|---|---|---|
RA1 | F | 74 | 30 | 7000 | 0.28 | 347 | 152 | 49 | NSAIDs + DMARDs |
RA2 | M | 69 | 4 | 7900 | 3.4 | 875 | 788 | 69 | MTX + anti-TNF-α |
RA3 | M | 69 | 4 | 4000 | 2.9 | 875 | 788 | 69 | MTX + anti-TNF-α |
RA4 | M | 76 | 10 | 5700 | 2.96 | 7.9 | 530 | 380 | MTX + anti-IL6 |
RA5 | F | 78 | 10 | 8000 | 3.78 | 727 | 386.7 | n.d | MTX |
RA6 | F | 76 | 15 | 4600 | 0.43 | 20.7 | 133.3 | 15.8 | MTX |
RA7 | M | 67 | 17 | 8000 | 0.73 | 570 | 256 | 78 | MTX + DMARDs |
RA8 | F | 71 | 15 | 7300 | 0.39 | 12.1 | 102.7 | 86 | MTX |
RA9 | F | 70 | 30 | 5600 | 0.14 | n.d | 86.8 | 7.9 | DMARDs |
RA10 | F | 75 | 25 | 3100 | 0.54 | 0.6 | 87 | 4.7 | MTX + DMARDs |
RA11 | F | 85 | 6 | 9200 | 2.13 | 80 | 190 | 228.2 | MTX + PSL |
RA12 | F | 74 | 10 | 5300 | 0.31 | 860 | 59.9 | 240 | MTX |
